Pro-Pharmaceuticals, Inc.

Pro-Pharmaceuticals' Pre-NDA Meeting Scheduled with FDA

Published in Medical Letter on the CDC and FDA, October 26th, 2008

Pro-Pharmaceuticals, Inc. (Amex: PRW) announced that a pre-New Drug Application ("NDA") meeting with the U.S. Food & Drug Administration ("FDA") is scheduled for December 22nd for DAVANAT(R) under Section 505 (b)(2) to be co-administered with 5-Fluorouracil (5-FU) to treat late-stage colorectal cancer patients.

"Our goal is to commercialize DAVANAT(R) and to generate revenue in 2009," said Theodore Zucconi, Ph.D., President, Pro-Pharmaceuticals, Inc. "In pre-clinical and clinical studies, DAVANAT(R) has improved efficacy and reduced toxicity of chemotherapies and biologics. We also are working on potential licensing agreements and have regional agreements in place to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2008-10-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry